December 8, 2023 03:04 PM ESTUpdated December 8, 09:15 PM

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win review voucher

Kyle LaHucik

Senior Reporter

Investors reacted negatively to bluebird bio’s pricing plans for its new sickle cell therapy, as well as the lack of a valuable priority review voucher …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win review voucher

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win re­view vouch­er

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win review voucher

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify